Uwe Platzbecker, MD

Articles

Unmet Needs and Future of Lower-Risk MDS

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Treatment Strategies and Sequencing in MDS

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Real-World Data for Luspatercept in Lower-Risk MDS

October 12th 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

Dr Platzbecker on the COMMANDS Trial in Lower-Risk MDS With Anemia

October 7th 2023

Uwe Platzbecker, MD, discusses key findings from the phase 3 COMMANDS trial with luspatercept in patients with lower-risk myelodysplastic syndrome with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

October 5th 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

October 5th 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

September 28th 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

September 28th 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Clinical Insights into the COMMANDS Trial

September 21st 2023

The expert panel reviews updated data from the COMMANDS trial on luspatercept in patients with lower-risk MDS and discusses their effect on clinical practice. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Myelodysplastic Syndrome: Overview of Diagnosis, Classification, and Treatment

September 21st 2023

A panel of expert hematologists give an overview of myelodysplastic syndrome, focusing on diagnosis, classification, and treatment practices.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

Summary of Unmet Needs and Future Directions in MDS

March 9th 2023

Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.

MDS/MPN-RS-T Overlap Syndromes

March 9th 2023

A brief discussion centered on MDS/MPN-RS-T overlap syndromes, considerations for diagnosis, available treatment options, and updates in the space.

Recent Data Updates in Higher-Risk MDS

March 2nd 2023

The panelists touch on emerging data in the higher-risk MDS space, including updates presented at ASH 2022.

Higher-Risk MDS: First- and Second-Line Therapies and Case 3 Presentation/Discussion

March 2nd 2023

The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.

Additional Updates in Second-Line Treatment of Lower-Risk MDS

February 23rd 2023

Experts summarize recent updates on other approved or emerging second-line therapies for lower-risk MDS.

MEDALIST Trial Updates: ASH 2022 and EHA 2022

February 23rd 2023

Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.

Case 2 Discussion and Considerations for Second-Line Treatment Selection

February 16th 2023

The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.

Case 2 Presentation: Lower-Risk MDS-RS With an SF3B1 Mutation

February 16th 2023

Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.

The Impact of p53 Mutations and 5q Deletions on Lower-Risk MDS Treatment Response

February 9th 2023

Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.